First new asthma treatment in a decade

There is new hope for those with “difficult to treat” asthma in the new year, with breakthrough biologic to be PBS listed on 1 Jan Nucala (mepolizumab) is the first therapy to be approved as an add-on treatment for with severe refractory eosinophilic asthma. Similar to Novartis’ Xolair (omalizumab), GSK’s Nucala (mepolizumab) is designed to